Synthesis and in vitro and in vivo evaluation of hypoxia- enhanced 111In-bombesin conjugates for prostate cancer imaging

Journal of Nuclear Medicine

Volumn 54, Issue 9, 2013, Pages 1605-1612

  Zhou, Zhengyuan ^a   Wagh, Nilesh K ^a   Ogbomo, Sunny M ^a   Shi, Wen ^a   Jia, Yinnong ^a   Brusnahan, Susan K ^a   Garrison, Jered C ^a,b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

2 nitroimidazole; BB2 receptor; Bombesin; Prostate cancer; Tumor hypoxia

Indexed keywords

2 NITROIMIDAZOLE DERIVATIVE; BOMBESIN; BOMBESIN 2 RECEPTOR; BOMBESIN RECEPTOR; DIAGNOSTIC AGENT; GASTRIN RELEASING PEPTIDE RECEPTOR; INDIUM BOMBESIN IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; INDIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; BIOSYNTHESIS; CANCER DIAGNOSIS; CHEMICAL STRUCTURE; CONJUGATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOLECULAR DYNAMICS; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT; 2-NITROIMIDAZOLE; ANIMAL; ANTIBODY SPECIFICITY; BB2 RECEPTOR; CELL HYPOXIA; CHEMISTRY; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; PROSTATE TUMOR; REPRODUCIBILITY; SCID MOUSE; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE; TUMOR HYPOXIA;

2-NITROIMIDAZOLE; BB2 RECEPTOR; BOMBESIN; PROSTATE CANCER; TUMOR HYPOXIA;

ANIMALS; BOMBESIN; CELL HYPOXIA; CELL LINE, TUMOR; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, SCID; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84887358740     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.117986     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol. 1999;155:2067-2076.
3. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152-1159.
4. Abd-Elgaliel WR, Gallazzi F, Garrison JC, et al. Design, synthesis, and biological evaluation of an antagonist: bombesin analogue as targeting vector. Bioconjug Chem. 2008;19:2040-2048.
5. Garrison JC, Rold TL, Sieckman GL, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: sideby- side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med. 2007;48:1327-1337.
6. Zhang X, Cai W, Cao F, et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med. 2006;47:492-501.
7. Hoffman TJ, Gali H, Smith CJ, et al. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med. 2003;44:823-831.
8. Milosevic M, Warde P, Ménard C, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res. 2012;18:2108-2114.
9. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266-276.
10. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995;22:265-280.
11. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49(suppl):129S-148S.
12. Bolton JL, McClelland RA. Kinetics and mechanism of the decomposition in aqueous solutions of 2-(hydroxyamino) imidazoles. J Am Chem Soc. 1989;111: 8172-8181.
13. Grosu AL, Souvatzoglou M, Roper B, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:541-551.
14. Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD, Wiebe LI. Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J Nucl Med. 1991;32:1764-1770.
15. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
16. Wagh NK, Zhou Z, Ogbomo SM, Shi W, Brusnahan SK, Garrison JC. Development of hypoxia enhanced 111In-labeled bombesin conjugates: design, synthesis, and in vitro evaluation in PC-3 human prostate cancer. Bioconjug Chem. 2012; 23:527-537.
17. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4:437-447.
18. Raleigh JA, Koch CJ. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem Pharmacol. 1990;40:2457-2464.
19. Garrison JC, Rold TL, Sieckman GL, et al. Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN (7-14) NH2 structural paradigm in a prostate cancer model. Bioconjug Chem. 2008;19: 1803-1812.
20. Waser B, Eltschinger V, Linder K, Nunn A, Reubi JC. Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177 Lu-AMBA. Eur J Nucl Med Mol Imaging. 2007;34:95-100.
21. Wang J, Klem J, Wyrick JB, et al. Detection of hypoxia in human brain tumor xenografts using a modified comet assay. Neoplasia. 2003;5:288-296.
22. Nordsmark M, Bentzen SM, Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode: an analysis of inter-and intratumour heterogeneity. Acta Oncol. 1994;33:383-389.
23. Rasey JS, Koh W-J, Grierson JR, Grunbaum Z, Krohn KA. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys. 1989;17:985-991.
24. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol. 2002; 20:680-687.
25. Melo T, Duncan J, Ballinger JR, Rauth AM. BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med. 2000;41:169-176.
26. Evans SM, Kachur AV, Shiue CY, et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F] EF1. J Nucl Med. 2000;41:327-336.
27. Vegt E, de Jong M, Wetzels JF, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049-1058.
28. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. 1995;55:3825-3834.
29. Pimm MV, Gribben SJ. Prevention of renal tubule re-absorption of radiometal (indium-111) labelled Fab fragment of a monoclonal antibody in mice by systemic administration of lysine. Eur J Nucl Med. 1994;21:663-665.
30. Christensen EI, Birn H. Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol. 2002;3:256-266.
31. Brezis M, Rosen S. Hypoxia of the renal medulla: its implications for disease. N Engl J Med. 1995;332:647-655.
32. de Jong M, Rolleman EJ, Bernard BF, et al. Inhibition of renal uptake of indium- 111-DTPA-octreotide in vivo. J Nucl Med. 1996;37:1388-1392.
33. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9-15.
34. van Eerd JE, Vegt E, Wetzels JF, et al. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med. 2006; 47:528-533.